个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Lu, S.[1] * ; Yu, Y.[1] ; Guo, Q.[2] ; Li, Y.[2] ; Zhong, D.[3] ; Gu, L.[3] ; Fang, J.[4] ; Han, S.[4] ; Pan, P.[5] ; Deng, P.[5] ; Liu, B.[6] ; Wang, M.[6] ; Wu, H.[7] ; Gao, F.[7] ; Lin, W.[8] ; Li, J.[8,11] ; Lv, D.[9] ; He, S.[9] ; Liu, Z.[10] ; Pan, C.[10] ; Li, J.[8,11] ; Tian, Y.[11] ; Yang, N.[8] ; Zhang, Y.[8] ; Liu, C.[12] ; Zhu, X.[12] ; Song, Q.[13] ; Yu, J.[13] ; Fan, S.[13] ; Ren, Y.[13] ; Shi, M.[13] ; Su, W.[13] ;
机构： [1]Shanghai Chest Hosp, Jinan, Peoples R China [2]Shandong Canc Hosp, Jinan, Peoples R China [3]Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China [4]Beijing Canc Hosp, Beijing, Peoples R China [5]Cent South Univ, Xiangya Hosp, Changsha, Peoples R China [6]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [7]Henan Canc Hosp, Zhengzhou, Peoples R China [8]Hunan Canc Hosp, Changsha, Peoples R China [9]Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China [10]Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China [11]Sichuan Canc Hosp, Chengdu, Peoples R China [12]Xinjiang Med Univ, Canc Hosp, Urumqi, Peoples R China [13]HUTCHMED Ltd, Shanghai, Peoples R China
出处：
ISSN：

关键词： savolitinib MET exon 14 NSCLC

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Shanghai Chest Hosp, Jinan, Peoples R China
推荐引用方式(GB/T 7714)：
Lu S.,Yu Y.,Guo Q.,et al.A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S92-S93.
APA：
Lu, S.,Yu, Y.,Guo, Q.,Li, Y.,Zhong, D....&Su, W..(2023).A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA：
Lu, S.,et al."A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S92-S93

相关文献

[1]Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation [2]Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations [3]Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study [4]Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China [5]Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. [6]Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study [7]The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable [8]Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study [9]Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial [10]Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial

资源点击量：53094 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号